Anders, it’s a good thing Dr. Linda Liau, Dr. Prins, Dr. Bosch, among others have continued to work on improving DCVax. In November we heard the results of a Phase II trial with L and Another immunotherapy which were positive. The good doctors’ work has shown us that there is synergy between DCVax and checkpoint inhibitors. Liau and Prins are working on finding bio markers that show if DCVax is working in a specific patient. They’ve already identified the gene types and methylation that works best with DCVax, though all types seem to respond. Then there are the iimprovements that have already been made to manufacturing that will (has) make DCVax more pure, more reliable thus we have can expect even longer lived patients. As for chemo/radiation, some of this bad stuff may be necessary to lighten the tumor load, but we have often speculated on this message board whether Doctors in the many paid/compassionate care cases, have chosen to move up DCVax treatments or do without portions or all of standard of care. I think that becomes an individual decision by doctors and their patients. And finally, what is LP doing with her new stem cell company? Possible cutting edge and synergetic with DCVax?
What I’m saying is the doctors and the company are ready to make improvements on DCVax that will keep it out ahead of the pack as soon as it sees approval, which I believe will happen.
I suggest that all longs should smile knowing that, as we approach top line data, the bears are now most worried that we’ll only make a pile of money on our investment for a few years.
News 
Market Data 
Discover 
